APA

Voest E. E., Neijt J. P., Keunen J. E., Dekker A. W., van Asbeck B. S., Nortier J. W., Ros F. E. & Marx J. J. (19930317). Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. : Cancer chemotherapy and pharmacology.

Chicago

Voest E E, Neijt J P, Keunen J E, Dekker A W, van Asbeck B S, Nortier J W, Ros F E and Marx J J. 19930317. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. : Cancer chemotherapy and pharmacology.

Harvard

Voest E. E., Neijt J. P., Keunen J. E., Dekker A. W., van Asbeck B. S., Nortier J. W., Ros F. E. and Marx J. J. (19930317). Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. : Cancer chemotherapy and pharmacology.

MLA

Voest E E, Neijt J P, Keunen J E, Dekker A W, van Asbeck B S, Nortier J W, Ros F E and Marx J J. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. : Cancer chemotherapy and pharmacology. 19930317.